Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

109.68
+1.241.14%
Post-market: 110.000.3200+0.29%18:55 EDT
Volume:1.98M
Turnover:216.74M
Market Cap:12.45B
PE:32.43
High:110.88
Open:107.08
Low:106.82
Close:108.44
52wk High:111.15
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:1.65
T/O Rate:1.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:86.72
PE(LYR):42.84

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Halozyme (HALO) and Vor Biopharma (VOR)

TIPRANKS
·
May 14

Stock Track | Halozyme Therapeutics Plummets 5.03% Intraday Amid Margin Compression and Earnings Volatility Concerns

Stock Track
·
May 14

Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative

Simply Wall St.
·
May 13

Halozyme Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
May 13

Halozyme price target lowered to $93 from $96 at Morgan Stanley

TIPRANKS
·
May 13

Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley

MT Newswires Live
·
May 12

These 10 'HALO' stocks protect your portfolio from the AI bubble

Dow Jones
·
May 12

Stock Track | Halozyme Therapeutics Soars 7.71% Intraday on Strong Q1 Earnings Beat and Analyst Optimism

Stock Track
·
May 12

Morgan Stanley Cuts Price Target on Halozyme Therapeutics to $93 From $96, Keeps Overweight Rating

MT Newswires Live
·
May 12

Analysts’ Top Healthcare Picks: Halozyme (HALO), MindWalk Holdings (HYFT)

TIPRANKS
·
May 12

Halozyme (HALO) Gets a Buy from H.C. Wainwright

TIPRANKS
·
May 12

Stock Track | Halozyme Therapeutics Soars 6.91% in Pre-Market on Q1 Earnings Beat

Stock Track
·
May 12

Financial Education Initiative: Huaxia Fund's 'Financial Reading Companion' Series Explores Commodity Price Trends and HALO Trading Strategy

Deep News
·
May 12

Halozyme Therapeutics Shares Rise in Extended Trade Following Results, Last up 3.4% at $68.68

THOMSON REUTERS
·
May 12

Halozyme beats Q1 revenue estimates, sets $1 billion buyback

Reuters
·
May 12

GUIDANCE:(HALO) Halozyme Therapeutics Expects Full Year 2026 Adjusted EPS Range $7.75 - $8.25, vs. FactSet Est of $8.06

MT Newswires Live
·
May 12

Earnings Flash (HALO) Halozyme Therapeutics Posts Q1 Revenue $376.7M, vs. FactSet Est of $358.6M

MT Newswires Live
·
May 12

Earnings Flash (HALO) Halozyme Therapeutics Posts Q1 Adjusted EPS $1.60, vs. FactSet Est of $1.55

MT Newswires Live
·
May 12

Halozyme Q1 2026 net income rises 27.06% to $150 million; revenue climbs 42% to $377 million

Reuters
·
May 12

BRIEF-Halozyme Therapeutics Q1 Adjusted EPS USD 1.6 Vs. IBES Estimate USD 1.53

Reuters
·
May 12